0001764013-23-000125.txt : 20231027
0001764013-23-000125.hdr.sgml : 20231027
20231027160403
ACCESSION NUMBER: 0001764013-23-000125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231025
FILED AS OF DATE: 20231027
DATE AS OF CHANGE: 20231027
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Levine Mark S.
CENTRAL INDEX KEY: 0001617236
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38906
FILM NUMBER: 231355500
MAIL ADDRESS:
STREET 1: 1601 TRAPELO ROAD
STREET 2: SUITE 284
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunovant, Inc.
CENTRAL INDEX KEY: 0001764013
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 832771572
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: 917-580-3099
MAIL ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp
DATE OF NAME CHANGE: 20190108
4
1
wk-form4_1698437034.xml
FORM 4
X0508
4
2023-10-25
0
0001764013
Immunovant, Inc.
IMVT
0001617236
Levine Mark S.
C/O IMMUNOVANT, INC.
320 W 37TH STREET, 6TH FLOOR
NEW YORK
NY
10018
0
1
0
0
Chief Legal Officer
0
Common Stock
2023-10-25
4
S
0
4107
34.66
D
310381
D
On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on October 19,
2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.66 - $34.83 per share, inclusive. The Reporting Person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the
range set forth in this footnote to this Form 4.
/s/ Eva Renee Barnett, attorney-in-fact for Mark S. Levine
2023-10-27